Bibliography
- Brakoulias V, Starcevic V, Berle D, et al. Further support for five dimensions of obsessive-compulsive symptoms. J Nerv Ment Dis 2013;201:452-9
- Jenike MA, Rauch SL. Managing the patient with treatment-resistant obsessive compulsive disorder: Current strategies. J Clin Psychiatry 1994;55:11-14
- NICE. Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. Clinical Guideline 31. 2005. Available from: www.nice.org.uk/guidelines.aspx?o=guidelines.completed [Cited 5 January 2011]
- Koran L, Simpson H. Guideline watch (March 2013): practice guideline for the treatment of patients with obsessive-compulsive disorder, in APA practice Guidelines. Am Psychiatric Assoc 2010
- Pizarro M, Fontenelle L, Paravidino D, et al. An updated review of antidepressants with marked serotonergic effects in obsessive–compulsive disorder. Expert Opin Pharmacother 2014;15(10):1391-401
- Heyman I, Mataix-Cols D, Fineberg N. Clinical Review: obsessive-compulsive disorder. BMJ 2006;333:424-9
- Erzegovesi S, Cavallini MC, Cavedini P, et al. Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 2001;21(5):488-92
- Mataix-Cols D, Rauch SL, Manzo PA, et al. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry 1999;156(9):1409-16
- Stein DJ, Andersen EW, Overo KF. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. Rev Bras Psiquiatr 2007;29(4):303-7
- Starcevic V, Brakoulias V. Symptom subtypes of obsessive-compulsive disorder: are they relevant for treatment? Aust NZJ Psychiatry 2008;42(8):651-61
- McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51(4):302-8
- Olatunji BO, Moretz MW, Wolitzky-Taylor MB, et al. Disgust vulnerability and symptoms of contamination-based OCD: descriptive tests of incremental specificity. Behav Ther 2010;41(4):475-90
- Eisen J, Greenberg BD, Mancebo M, et al. OCD Subtypes. American Psychiatric Association, Toronto CA; 2006
- Coles ME, Frost RO, Heimberg RG, et al. “Not just right experiences”: perfectionism, obsessive-compulsive features and general psychopathology. Behav Res Ther 2003;41(6):681-700
- McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57(8):794